Cabot Wealth Management Inc. Sells 100 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cabot Wealth Management Inc. lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,615 shares of the company’s stock after selling 100 shares during the period. Cabot Wealth Management Inc.’s holdings in IDEXX Laboratories were worth $2,321,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $31,000. Ashton Thomas Securities LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $37,000. Finally, Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $38,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on IDXX shares. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock worth $6,161,276 over the last quarter. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $452.77 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The firm has a fifty day moving average price of $431.92 and a 200-day moving average price of $452.28. The stock has a market cap of $37.08 billion, a PE ratio of 42.43, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.